What is the Medicare GLP-1 Bridge?

A short-term demonstration run by CMS that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs at a $50 copay. It runs from July 1, 2026 through December 31, 2027, and operates outside the normal Part D coverage and payment flow. CMS extended it through the end of 2027 after the BALANCE Model did not launch in 2027.

You must be 18 or older with Medicare Part D coverage, and meet one of three clinical routes when you start therapy: a BMI of 35 or higher; a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

You are not eligible if you already get GLP-1 drugs covered through your Part D plan, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Those last three are not disqualifications from treatment — Medicare notes your Part D plan might cover your GLP-1s in those cases. The Bridge exists for weight management where Part D does not already cover you.

Does the $50 count toward my out-of-pocket maximum?

No, and this is the most important catch. Because the Bridge operates outside the Part D benefit, the Part D deductible does not apply, no part of the $50 copay counts toward your true out-of-pocket (TrOOP) costs, and there is no low-income subsidy available for LIS beneficiaries. Medicare states the cost is $50 per month regardless of your income level.

What does my doctor need to do?

Send a prescription for a covered GLP-1 to the pharmacy and complete a prior authorization when requested. Your provider must also certify that you are using the medication as part of a lifestyle program focused on diet and exercise. Once approved, your prior authorization is valid through December 31, 2027 including refills and dose changes — unless you switch to a different GLP-1.

Is it available everywhere?

Yes. CMS states the program is available nationwide, including all states and U.S. territories. It covers standalone Part D drug plans, Medicare Advantage plans with drug coverage, Special Needs Plans, employer or union group waiver plans, and the Limited Income Newly Eligible Transition program.

What happens after 2027?

Not established. CMS describes the Bridge as a short-term demonstration running through December 31, 2027, intended in part to collect data on GLP-1 utilisation ahead of potential implementation of the BALANCE Model in Part D. What replaces it, if anything, has not been announced — so treat $50/month as a defined window rather than a permanent arrangement.

Medicare GLP-1 Bridge: $50/Month Coverage Explained (2026

Q: Which drugs are covered?

Medicare lists three: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound — KwikPen only. The program specifically does not cover single-dose Zepbound vials or pens, which is an easy detail to miss when your prescriber writes the script.

What it is

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs at a $50 copay. It launched on July 1, 2026 and runs through December 31, 2027.

Structurally it sits outside the normal Part D benefit's coverage and payment flow. That has real consequences for beneficiaries, which we cover below — but it also means Part D sponsors do not carry risk for these drugs and do not have to opt in for you to access them. In 2026 CMS uses a single central processor to handle prior authorisation, claims, and payment to pharmacies.

CMS extended the program through the end of 2027 after the BALANCE Model did not launch in 2027, describing the extension as a way to collect additional data on GLP-1 utilisation to share with Part D plan sponsors.

Which drugs are covered

Drug	Form	Covered?
Foundayo	Tablet	Yes
Wegovy	Injection or tablet	Yes
Zepbound	KwikPen	Yes
Zepbound	Single-dose vials and pens	No

That last row matters more than it looks. Zepbound is dispensed in several formats, and the Bridge covers only the KwikPen. If your prescriber writes for single-dose vials out of habit, the prescription falls outside the program. It is worth naming the format explicitly when you talk to them.

Who qualifies

You must be 18 or older with Medicare drug coverage (Part D), and meet one of three clinical routes when you start GLP-1 therapy.

BMI 35 or higher

No additional condition required

BMI 30 or higher

Plus one of: diastolic heart failure (heart failure with preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher

BMI 27 or higher

Plus one of: prediabetes, a previous heart attack or stroke, or blocked arteries in the legs or arms (peripheral artery disease) with symptoms

Note how much more generous the lower routes are than the headline. A great deal of coverage describes the Bridge as “BMI 35 and above,” which is only the first of three doors. If you have prediabetes and a BMI of 27, or chronic kidney disease at stage 3a and a BMI of 30, you may qualify without ever approaching 35.

Which plan types count: standalone Medicare drug plans (PDP), Medicare Advantage coordinated care plans with drug coverage including HMO, HMOPOS, and Local and Regional PPO plans (MA-PD), Special Needs Plans (SNP), Employer or union group waiver plans (EGWP), and the Limited Income Newly Eligible Transition (LI NET) program.

Who is excluded, and why it is not bad news

Medicare states you are not eligible if you:

Already get GLP-1 drugs covered through your Part D plan
Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease

Both exclusions are less discouraging than they read. The Bridge exists to fill a gap where Part D does not already cover you — so if your plan covers your GLP-1, you do not need it. And Medicare explicitly notes that for type 2 diabetes, sleep apnea, or fatty liver disease, your Part D plan might cover your GLP-1s through the ordinary benefit. You are being routed, not refused.

The four catches

1. The $50 does not count toward your out-of-pocket costs

Because the Bridge sits outside the Part D benefit, CMS states the Part D deductible does not apply and no part of the $50 counts toward your true out-of-pocket (TrOOP) costs. If you take other expensive medications, this spending does not move you toward catastrophic coverage. It is $600 a year that does not count for anything else.

2. There is no low-income subsidy

CMS states there is no low-income subsidy (LIS) provided for LIS beneficiaries under the Bridge, and Medicare notes the cost is $50 per month no matter your income level. For most Medicare drug spending, LIS beneficiaries pay dramatically less. Here they pay the same $50 as everyone else, which makes this program proportionally hardest on the people with the least.

3. It ends December 31, 2027

This is a demonstration, not a benefit. CMS has not announced what follows. GLP-1 treatment for weight management is generally long-term, so starting on a program with a published end date means planning for what happens when it closes.

4. Your provider must certify a lifestyle program

Medicare requires your provider to certify that you are using the GLP-1 as part of a lifestyle program focused on diet and exercise. This is not onerous, but it does mean your prescriber needs to be engaged with the requirement rather than simply writing a script.

How to actually get it

Confirm you have qualifying Part D coverage and check your BMI against the three routes above.
Check whether your Part D plan already covers a GLP-1. If it does, you are not eligible for the Bridge — and you may not need it.
Talk to your provider about which covered drug fits. Name the format: Zepbound KwikPen, not vials.
Your provider sends the prescription to the pharmacy and completes a prior authorisation when requested, including the lifestyle-program certification.
Your pharmacy may ask for your Medicare Number or the last four digits of your Social Security Number to process it.
You will get a letter confirming your drug is covered under the Medicare GLP-1 Bridge. The prior authorisation is valid through December 31, 2027, including refills and dose changes — unless you switch to a different GLP-1.

How it compares to paying cash

For anyone who qualifies, $50 a month beats every other route we have found. The closest cash alternatives are the Wegovy pill at $149/month through NovoCare Pharmacy, or Zepbound at $299 through LillyDirect — and those rise substantially at higher doses while the Bridge copay stays flat regardless of dosage.

Several providers also work with the program. Walgreens promotes it directly, and Found quotes a $50/month figure for eligible Medicare Part D members. If your Part D plan already covers GLP-1s — which disqualifies you from the Bridge — that ordinary coverage may still be cheaper than anything on our cost ranking.

If you were turned away elsewhere

Several telehealth companies exclude anyone with government coverage — LifeMD states that Medicare, Medicaid, TRICARE or Medicare Supplement coverage makes you ineligible for its GLP-1 programs, primary or secondary. That is a commercial restriction, not a clinical judgement about you. The Bridge, ordinary Part D coverage, and NovoCare's self-pay route all remain open.

The Medicare GLP-1 Bridge: $50 a Month